ijms-logo

Journal Browser

Journal Browser

Special Issue "Roles of the Immune System in Cancer"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 31 March 2022.

Special Issue Editor

Prof. Dr. Camillo Palmieri
E-Mail
Guest Editor
Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Campus Salvatore Venuta-Viale Europa, 88100 Catanzaro, Italy
Interests: clinical biochemistry; leukemia and lymphoma; molecular biomarkers; immunotherapy; T- and B-cell biology
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

While the inherent genetic mechanisms of early cancer cells are likely to initiate cancer development, the immune system plays a crucial role in determining the following outcomes of cancer progression. The success of new immunotherapeutic strategies demonstrates that intervention in the interplay between immune and tumor cells can positively modify an unfavorable evolution of the disease. At the same time, the real effectiveness of this intervention cannot be separated from an exhaustive understanding of the particular history of each individual tumor and its dynamic relationship with the immune system.

This Special Issue aims to cover all fields of basic research in the study of tumor immunology. It welcomes original research, reviews, and short communication articles on the cellular and molecular mechanisms of antitumor adaptive and innate immunity, as well as the innovative biomarkers involved in predicting responses to immunotherapy in cancer. This Special Issue welcomes papers covering, but not limited to, the following topics:

- The role of immune cells in the tumor microenvironment; 

- Tumor-associated macrophages in cancer progression and response;

- Natural killer cells in cancer immunotherapy;

- Myeloid-derived suppressor cells;

- Cancer stem cells and epithelial-to-mesenchymal transition; 

- Ageing and tumor immune escape;

- Chimeric antigen receptor gene therapy in cancer;

- New checkpoint inhibitor pathways;

- Identification of novel tumor antigens for clinical evaluation;

- Immune repertoire analysis and innovative biomarkers

Prof. Camillo Palmieri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

Case Report
Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune–Biological Evaluation and Case Report
Int. J. Mol. Sci. 2021, 22(12), 6246; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22126246 - 10 Jun 2021
Cited by 2 | Viewed by 713
Abstract
Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of a patient [...] Read more.
Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of a patient with a metastatic bladder cancer who developed myositis signs (M) and a myasthenia-like syndrome (MLS) during treatment with pembrolizumab. The patient presented an autoimmunity-associated HLA haplotype (HLA-A*02/HLA-B*08/HLA-C*07/HLA-DRB1*03) and experienced an increase in activated CD8 T-cells along the treatment. The symptomatology regressed after pembrolizumab discontinuation and a pyridostigmine and steroids-based therapy. This is the first report of concurrent M and MLS appearance in cancer patients receiving pembrolizumab. More efforts are needed to define early the risk and the clinical meaning of irAEs in this setting. Full article
(This article belongs to the Special Issue Roles of the Immune System in Cancer)
Show Figures

Figure 1

Back to TopTop